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Abstract
Background: Germinal center kinase-like kinase (GLK, also termed MAP4K3), a member of the MAP4K family, may
regulate gene transcription, apoptosis and immune inflammation in response to extracellular signals. The enhanced
expression of GLK has been shown to correspond with disease severity in patients with systemic lupus
erythematosus. We investigated the role of GLK in the pathogenesis of adult-onset Still’s disease, which shares
some similar clinical characteristics with systemic lupus erythematosus.
Methods: The frequencies of circulating GLK-expressing T-cells in 24 patients with active adult-onset Still’s disease
and 12 healthy controls were determined by flow cytometry analysis. The expression levels of GLK proteins and
transcripts were evaluated in peripheral blood mononuclear cells by immunoblotting and quantitative PCR. Serum
levels of T helper (Th)17-related cytokines, including IL-1b, IL-6, IL-17 and TNF-a, were measured by ELISA.
Results: Significantly higher median frequencies of circulating GLK-expressing T-cells were observed in patients
with adult-onset Still’s disease (31.85%) than in healthy volunteers (8.93%, P <0.001). The relative expression levels
of GLK proteins and transcripts were also significantly higher in patients with adult-onset Still’s disease (median,
1.74 and 2.35, respectively) compared with those in healthy controls (0.66 and 0.92, respectively, both P <0.001).
The disease activity scores were positively correlated with the frequencies of circulating GLK-expressing T-cells (r =
0.599, P <0.005) and the levels of GLK proteins (r = 0.435, P <0.05) or GLK transcripts (r = 0.452, P <0.05) in patients
with adult-onset Still’s disease. Among the examined Th17-related cytokines, elevated levels of serum IL-6 and IL-17
were positively correlated with the frequencies of circulating GLK-expressing T-cells and the levels of GLK proteins
as well as transcripts in patients with adult-onset Still’s disease. GLK expression levels decreased significantly after
effective therapy in these patients.
Conclusions: Elevated expression levels of GLK and their positive correlation with disease activity in patients with
adult-onset Still’s disease indicate that GLK may be involved in the pathogenesis and act as a novel activity
biomarker of this disease.




1Division of Allergy, Immunology and Rheumatology, Taichung Veterans
General Hospital and Faculty of Medicine, National Yang Ming University,
Taiwan
Full list of author information is available at the end of the article
Chen et al. BMC Medicine 2012, 10:84
http://www.biomedcentral.com/1741-7015/10/84
Clinical Biomarkers
© 2012 Chen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
Mitogen-activated protein kinases (MAPKs) comprise a
family of cytoplasmic serine/threonine protein kinases
that are involved in the regulation of key cellular pro-
cesses including gene induction, cell proliferation, and
inflammatory responses [1,2]. There are three major
families of MAPKs, namely p38 MAPK, extracellular-
regulated protein kinase and c-Jun N-terminal kinase
(JNK) [3]. Wong et al. showed that activation of NF-B,
JNK and p38 MAPK play crucial roles in cytokine-
mediated signaling pathways in T helper (Th) cells [4].
Moreover, the abnormal activation of intracellular
MAPK upon IL-18- stimulation may account for hyper-
activity of peripheral lymphocytes in systemic lupus
erythematosus (SLE) [5]. A recent study demonstrated
that activation of p38 MAPK contributes to Th17-cell
effector function as well as the pathogenesis of Th17-
mediated disease [6].
MAPK activation is mediated by upstream MAPK
kinases, termed MAP2Ks (MKKs) and MAP3Ks (MKKKs).
MAP4Ks, upstream kinases of MAP3Ks, likely regulate
gene transcription, cell growth, apoptosis, and immune
inflammation in response to extracellular signals [7,8].
Germinal center kinase-like kinase (GLK; also termed
MAP4K3) is a member of the MAP4K family, which is a
subfamily of the sterile 20 protein-like serine/threonine
kinases [7]. GLK contains a conserved N-terminal kinase
domain, a conserved C-terminal citron homology domain
and proline-rich motifs in the middle portion [7]. Lam et
al. identified GLK as a novel inducer of apoptosis [9], and
apoptosis plays an important role in the pathogenesis of
autoimmune diseases [10,11]. Our recent study showed an
increased GLK expression that positively correlated with
disease severity in patients with SLE [12]. In addition, pre-
vious studies showed that GLK-deficient mice were resis-
tant to experimental autoimmune encephalomyelitis
(EAE) [12], mediated mainly by Th17 cells [13].
Adult-onset Still’s disease (AOSD) is an inflammatory
disorder characterized by fever, rash, arthritis, variable
multisystemic involvement, and an increase of acute phase
reactants [14,15]. Our previous studies and other reports
have shown that the levels of proinflammatory cytokines
including IL-1b, IL-6, IL-18 and TNF-a are increased in
patients with AOSD [16-19]. Furthermore, Th17 cells play
an important role in the pathogenesis of AOSD [20].
These observations and a significant association of GLK
with lupus disease activity [12] lead us to hypothesize that
GLK may play a role in the pathogenesis of AOSD, which
shares partial clinical manifestations with SLE. However,
there is no data concerning GLK expression in AOSD.
In this study, we investigated whether GLK and Th17-
related cytokines were involved in the pathogenesis of
AOSD. The associations of GLK expression with disease
activity and clinical characteristics were examined in
patients with AOSD. The changes in GLK expression dur-




Twenty-four consecutive patients visiting Taichung
Veterans General Hospital, Taiwan, with active
untreated AOSD (15 women and 9 men, mean age ±SD,
33.3 ±9.9 years) fulfilling the Yamaguchi criteria [21]
were enrolled. Patients with infections, malignancies or
other rheumatic diseases were excluded. The disease
activity scores (range, 0 to 12) for each patient were
assessed according to the criteria described by Pouchot
et al. [22]. After an initial determination of the levels of
circulating GLK-expressing T-cells and Th17-related
cytokines, all patients with AOSD received corticoster-
oids and non-steroidal anti-inflammatory drugs. The
disease-modifying anti-rheumatic drugs used were meth-
otrexate (20 patients), hydroxychloroquine (18 patients),
sulfasalazine (8 patients), and azathioprine (3 patients).
Twelve age-matched healthy volunteers (eight women
and four men, mean age 32.4 ±8.2 years) who had no
rheumatic disease served as normal controls. Peripheral
blood was collected using endotoxin-free heparinized
vacuum tubes (KABI-ET; Chromogenix, Antwerp, Bel-
gium) to avoid cytokine production during the interval
between sampling and culture. The Ethics Committee of
Clinical Research, Taichung Veterans General Hospital,
approved this study (No. C10130) and written consent
was obtained from all participants according to the
Declaration of Helsinki.
Quantitation of circulating GLK-expressing T-cells using
flow cytometry analysis
Circulating GLK-expressing T-cells were quantified using
flow cytometry analysis according to the technique
described in a recent study [12]. Antibodies for GLK were
generated by immunizing rabbits with individual peptides
[12]. Briefly, peripheral blood mononuclear cells (PBMCs)
were harvested, washed with cold PBS, and stained with
the indicated antibodies for 30 min on ice. PBMCs were
then treated with Golgi-stop (10 μg/mL of Brefeldin A,
Sigma, Schnelldorf, Deisenhofen, Germany) without any
other stimulation and then stained with anti-CD3-allophy-
cocyanin -Cy7,, anti-CD4-pacidic blue and anti-CD8-peri-
dinin chlorophyll protein cyanin 5.5 (all BD Pharmingen,
San Diego, CA, USA ), at room temperature (RT). For
intracellular staining, PBMCs were permeabilized in
200 μL Cytofix/Cytoperm buffer (BD Biosciences, San
Diego, CA, USA) for 2 h and washed with Perm-Wash
buffer. The pellet was incubated with 100 μL Reagent 2,
saponin (Beckman Coulter, Brea, CA, USA) for 5 min
at in the dark. Samples were washed twice with 0.1%
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BSA-PBS, and incubated with phycoerythrin (PE)-conju-
gated GLK-specific mAb (eBiosciences, San Diego, CA,
USA) for 30 minutes at in the dark. An isotype control
IgG1-PE (eBiosciences) was used for GLK staining at RT
in the dark. After staining, the cells were washed and
immediately analyzed using flow cytometry (Beckman
Coulter). Lymphocytes were gated on the basis of forward
and size scatter properties, and at least 10,000 CD3+ cells
were analyzed. Data were collected using FACSCanto II
flowcytometer (BD Biosciences) and analyzed by FlowJo
software.
Western blotting for GLK expression
For immunoblotting analysis, samples of purified T-cell
were performed as described in our recent study [12]. For
GLK, an equal amount of cell extracts from each set of
experiments were fractionated on 6% to 8% SDS-PAGE in
running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS).
The gel was run at 90 V for 30 min then at 130 V until
the blue dye front reached the bottom. The gel was trans-
ferred to polyvinylidene difluoride membrane in transfer
buffer (50 mM Tris, 384 mM glycine, 20% methanol) at
21 V for 1 h with the Trans-Blot SD Semi-Dry Electro-
phoretic Transfer Cell (Bio-Rad, Hercules, CA, USA). The
membranes were blocked with 5% BSA in Tris buffered
saline with Tween (TBST) (150 mM NaCl, 20 mM Tris-
HCl (pH 7.4), 0.1% Tween-20 ) at RT for 1 h then probed
with Anti-GLK (1:1,000), which was generated by immu-
nizing rabbits with the appropriate peptide and anti-b-
tubulin (1:1,000 T4026, Sigma, St. Louis, Missouri, USA)
at 4°C overnight. The membranes were washed about
three times with TBST, followed by incubation with per-
oxidase-conjugated secondary antibody (1:6,000) at RT for
1 h. The membranes of antibody reaction were washed
three times with TBST and performed using the enhanced
Immobilon Western Chemiluminescent HRP Substrate
(WBKLS0500, Millipore, Billerica, Massachusetts, USA),
exposed with a MegaCam 810 scientific grade CCD cam-
era (UVP, LLC, Upland, CA, USA). The relative expression
level of GLK protein was normalized to b-tubulin, and
values were expressed relative to the control.
Quantitative PCR for GLK expression
PBMCs were immediately isolated from venous blood
using Ficoll-Paque PLUS (GE Healthcare Biosciences,
Uppsala, Sweden) density gradient centrifugation. Total
cellular RNA was obtained from PBMCs by the guanidi-
nium isothiocyanate method [23] and was quantified by
spectrophotometry at 260 nm. A 2.5 μg RNA aliquot was
reverse transcribed with 200 U of Moloney murine leuke-
mia virus reverse transcriptase (Fermentas, Thermo
Fisher Scientific Inc.,Glen Burnie Maryland,USA) accord-
ing to standard procedures. GLK mRNA expression
levels were determined by quantitative PCR (qPCR) assay
supplied in a TaqMan PCR Core Reagent Kit (Applied
Biosystems, Foster City, CA, USA). Primers specific for
GLK and the internal control glyceraldehydes-3-phos-
phate dehydrogenase (GAPDH) were obtained from
Applied Biosystems. The purity of PCR products was
assessed by dissociation curve plots. To standardize
mRNA levels of GLK, transcript levels of the housekeep-
ing gene GAPDH were also determined in parallel for
each sample. The relative expression level of GLK was
calculated with comparative threshold cycle (Ct) method
and evaluated by:
2−Ct,Ct = Patient(CtGLK gene - CtGAPDH) - Mean of controls(CtGLK gene - CtGAPDH).
Determination of serum levels of soluble IL-2 receptor
and Th17-related cytokines
Serum soluble IL-2 receptor (sIL-2R) levels were deter-
mined using an ELISA kit (Cellfree; Endogen Inc.,
Woburn, MA, USA). Serum levels of IL-1b, IL-6, IL-17A
and TNF-a were determined in patients with AOSD and
in healthy controls (HCs) using ELISA according to the
manufacturer’s instructions (eBiosciences).
Statistical analysis
Results are presented as the mean ±SD or median
(interquartile range). The nonparametric Kruskal-Wallis
test was used for between-group comparison of the fre-
quencies of circulating GLK-expressing T-cells, the
expression levels of GLK transcript and protein, and
serum levels of Th17-related cytokines. When this test
showed significant differences, then the exact P-values
were determined using the Mann-Whitney U test. The
correlation coefficient was calculated using the nonpara-
metric Spearman’s rank correlation test. Wilcoxon
signed rank test was employed to compare the levels of
circulating GLK-expressing T-cells and the expression
levels of GLK during follow-up in patients with AOSD
after effective therapy. A P <0.05 was considered
significant.
Results
Clinical characteristics of patients with adult-onset Still’s
disease
As illustrated in Table 1, all 24 patients with active
untreated AOSD had daily spiking fevers (≥39°C). Other
common manifestations included evanescent rash (n =
20, 83.3%), sore throat (n = 17, 70.8%) and arthritis (n =
15, 62.5%). Lymphadenopathy and hepatosplenomegaly
were noted in 10 (41.7%) and six (25.0%) patients,
respectively. There were no significant differences in age
on entry to this study or the proportion of women
between the patients with AOSD and HCs.
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Increased frequencies of circulating GLK-expressing
T-cells in patients with adult-onset Still’s disease
Representative examples of flow cytometry contour plots
of GLK expression in peripheral blood CD3+ T-cells,
CD4+ T-cells and CD8+ T-cells of one patient with
active AOSD and one HC are shown in Figure 1A and
1B, respectively. Significantly higher median frequencies
of circulating GLK-expressing CD3+ T-cells were
observed in patients with active AOSD (median =
31.85%, interquartile (IQ) range 21.21% to 48.84%) than
in HCs (median = 8.93%, IQ range 6.81% to 12.08%;
P <0.001, Figure 1C).
Increased expression of GLK transcripts and proteins in
patients with adult-onset Still’s disease
As shown in Figure 1D, significantly greater fold increases
in relative expression of GLK transcripts were observed in
patients with active AOSD (median = 2.35, IQ range 1.66
to 3.88) than in HCs (median = 0.92, IQ range 0.63 to
1.37; P <0.001). Similarly, patients with active AOSD had
increased expression of GLK in the lysates of purified
T-cells determined by western blotting (Figure 1E). The
relative expression levels of GLK proteins in patients with
active AOSD (median = 1.74, IQ range 1.47 to 2.95) were
significantly higher than those in controls (median = 0.66,
IQ range 0.54 to 0.94; P <0.001, Figure 1F).
Increased serum levels of Th17-related cytokines in
patients with adult-onset Still’s disease
As shown in Figure 2, patients with active AOSD had sig-
nificantly higher median levels of serum IL-6 (median =
474.81 pg/mL, IQ range 156.42 pg/mL to 987.55 pg/mL),
IL-17A (median = 306.80 pg/mL, IQ range 152.17 pg/mL
to 503.70 pg/mL) and TNF-a (median = 51.85 pg/mL, IQ
range 23.63 pg/mL to 65.93 pg/mL) compared with those
in HCs (median = 85.78 pg/mL, IQ range 31.13 pg/mL to
189.98 pg/mL, P <0.001 for IL-6; median = 70.90 pg/mL,
IQ range 51.42 pg/mL to 124.53 pg/mL, P <0.001 for
IL-17A; and median = 24.66 pg/mL, IQ range 10.50 pg/
mL to 37.76 pg/mL, P <0.01 for TNF-a). However, there
was no significant difference in serum IL-1b levels
between patients with AOSD and HCs.
Correlation between GLK expression and disease activity
as well as cytokines in patients with adult-onset Still’s
disease
As illustrated in Table 2, the frequencies of circulating
GLK-expressing CD3+ T-cells were positively correlated
with disease activity, including clinical activity scores,
C-reactive protein levels, ferritin levels and serum levels of
sIL-2R, which reflected T-cell activation in patients with
AOSD. Similarly, the relative expression levels of GLK
proteins and transcripts were positively correlated with
clinical activity scores and sIL-2R levels in patients with
AOSD. Among the Th17-related cytokines, GLK expres-
sion levels were positively correlated with serum levels of
IL-6 and IL-17A. However, there was no significant corre-
lation of GLK expression with clinical manifestations in
our patients with AOSD (data not shown).
Changes in the levels of GLK expression in patients with
adult-onset Still’s disease after effective therapy
Twelve patients with AOSD were available for examina-
tion both at the active phase and at the remission phase.
As shown in Figure 3, the percentages of circulating GLK-
expressing T-cells and the relative expression levels (fold)
of GLK proteins as well as transcripts were significantly
decreased (mean ± standard error of the mean, 45.77
±5.58% versus 20.11 ±2.53%; 3.01 ±0.49 versus 0.93 ±0.17;
and 3.45 ±0.56 versus 1.21 ±0.38, respectively, all
P <0.005), paralleling clinical remission and the decrease
in serum levels of sIL-2R (747.8 ±131.8 pg/mL versus
Table 1 Demographic data and clinical characteristics of patients with adult-onset Still’s disease and healthy controls
Characteristics Adult-onset Still’s disease (n = 24) Healthy controls (n = 12)
Age at study entry (years) 33.3 ±9.9 32.4 ±8.2
Proportion of females 15 (62.5%) 8 (66.7%)
Fever (≥38°C) 24 (100%) NA
Evanescent rash 20 (83.3%) NA
Sore throat 17 (70.8%) NA
Arthritis 15 (62.5%) NA
Lymphadenopathy 10 (41.7%) NA
Liver dysfunctiona 10 (41.7%) NA
Hepatosplenomegaly 6 (25.0%) NA
Clinical activity score 5.83 ±1.34 NA
C-reactive protein (mg/dL) 3.3 ±0.4 NA
Ferritin levels (μg/L) 692.9 ±103.6 NA
Soluble IL-2R levels (pg/mL) 563.5 ±87.5 NA
Data are presented as mean ±SD or number (percentage). aLiver dysfunction was defined as alanine aminotransferase level ≧40 IU/L. NA: not applicable; IL-2R:
interleukin-2 receptor.
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229.1 ± 38.5 pg/mL, P <0.005) in patients with AOSD after
effective therapy.
Discussion
This study is the first investigation to demonstrate GLK
overexpression in patients with active AOSD relative to
HCs. The advent of flow cytometry analysis of intracellu-
lar signaling molecules [24] has greatly expanded the
opportunities to study a single cell in heterogeneous cell
populations. In the present study, CD3+ T-cells, includ-
ing CD4 and CD8 subsets, demonstrated increased GLK
expression in patients with active AOSD. Our results also
Figure 1 The GLK expression levels in T cells from patients with adult-onset Still’s diseases and healthy controls. Representative
examples of flow cytometry contour plots of intracellular GLK production in CD3+ T-cells, CD4+ T-cells, and CD8+ T-cells were obtained from
peripheral blood of (A) one patient with AOSD and (B) one healthy control. (C) The frequencies of circulating GLK-expressing CD3+ T-cells were
obtained from 24 patients with active AOSD and 12 HC. (D) The comparison in the relative expression levels of GLK transcript between patients
with AOSD and HC. (E) Immunoblot analyses of GLK expression in the lysates of peripheral blood T cells from patients with AOSD and HC. (F)
The comparison in the relative expression levels of GLK protein between patients with active AOSD and HC. Horizontal bar indicates median
value. *P-value was determined by Mann-Whitney U test. AOSD: adult-onset Still’s disease; GLK: germinal center kinase-like kinase; HC: healthy
control.
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showed significantly elevated frequencies of circulating
GLK-expressing T-cells, which correlated with disease
activity, including clinical activity scores and serum ferri-
tin levels, in patients with AOSD. Moreover, a parallel
decrease in GLK production with disease remission was
found in these patients. These data concerning patients
with AOSD were similar to the results of our recent
study showing elevated levels of circulating GLK-expres-
sing T-cells correlating with activity index in patients
with SLE [12], suggesting that GLK overexpression plays
an important role in AOSD pathogenesis, and is thus a
potential activity marker of this disease. However, a large
prospective study should be conducted to confirm the
findings presented here.
To verify GLK expression at the protein and transcript
levels in patients with AOSD, western blotting and qPCR
for GLK expression were performed in peripheral blood
lymphocytes from our patients with active untreated
AOSD. We have demonstrated that the relative expression
levels of GLK proteins and transcripts were significantly
Figure 2 The comparison in serum levels of Th17-related cytokines from patients with active adult-onset Still’s disease and healthy
controls. (A) IL-1b, (B) IL-6, (C) IL-17A, and (D) TNF-a. Horizontal bar indicates median value. *P-value was determined by Mann-Whitney U test.
AOSD: adult-onset Still’s disease; HC: healthy control.
Table 2 The correlations between the frequencies of circulating GLK-expressing T-cells, the relative expression levels





Relative expression levels of GLK
protein
Relative expression levels of GLK
transcript




Ferritin (μg/L) 0.508* 0.296 0.318
Soluble IL-2R (pg/mL) 0.865*** 0.569** 0.803***
IL-1b (pg/mL) 0.281 0.152 0.063
IL-6 (pg/mL) 0.822*** 0.423* 0.547**
IL-17A (pg/mL) 0.787*** 0.699*** 0.740***
TNF-a (pg/mL) 0.295 0.177 0.310
GLK: germinal center kinase-like kinase; IL: interleukin; IL-2R: interleukin-2 receptor; TNF-a: tumor necrosis factor-alpha. *P <0.05, **P <0.005, ***P <0.001 obtained
by the nonparametric Spearman’s rank correlation test.
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higher in our patients than in HCs. Moreover, the positive
correlations between the frequencies of circulating GLK-
expressing T-cells and the expression levels of GLK pro-
teins in our study are consistent with the findings of
previous studies showing that intracellular flow cytometry
and western blotting are equivalent assays for measuring
MAPK signaling status [25,26]. In addition, the expression
levels of GLK proteins as well as transcripts were
Figure 3 Correlation between GLK expression and disease activity parameters as well as cytokines in patients with adult-onset Still’s
disease. The correlation between the frequencies of circulating GLK-expressing T-cells and (A) disease activity score, activity parameters
including (B) serum ferritin levels, (C) C-reactive protein levels and (D) soluble interleukin-2 receptor levels, and serum levels of cytokines
including (E) IL-1b, (F) IL-6, (G)TNF-a and (H) IL-17A from 24 patients with adult-onset Still’s disease. Correlation coefficients (g) and P-value were
obtained by the nonparametric Spearman’s rank correlation test. AOSD: adult-onset Still’s disease; CRP: C-reactive protein; GLK: germinal center
kinase-like kinase; IL: interleukin; sIL-2R: soluble interleukin-2 receptor levels; TNF-a: tumor necrosis factor-alpha.
Chen et al. BMC Medicine 2012, 10:84
http://www.biomedcentral.com/1741-7015/10/84
Page 7 of 10
significantly correlated with clinical activity scores in our
patients with AOSD. These data provide the first direct
and robust evidence of GLK overexpression in the T-cells
of patients with AOSD.
Accumulating evidence indicates that Th17 cells play
an important role in the pathogenesis of both AOSD and
SLE [20,27,28]. IL-6 synergizes with IL-1b to enhance the
differentiation and generation of Th17 cells [29]. Th17
cells can secrete IL-17, a pleiotropic cytokine which
participates in tissue inflammation by inducing the
expression of proinflammatory cytokines and chemokines
[30-32]. Our recent study showed that GLK-deficient
mice are resistant to the development of EAE and
showed decreased Th17 responses [12]. The results from
in vitro T-cell differentiation assays also indicate that
GLK plays a positive role in Th17 cell differentiation
[12]. In the present study, the results revealed elevated
serum levels of Th17-related cytokines, IL-6 and IL-17A,
which were correlated with the expression levels of GLK
in T-cells from patients with AOSD. Our data also
Figure 4 Changes in the levels of circulating GLK-expressing T-cells, the expression levels of GLK proteins as well as transcripts, and
serum levels of soluble interleukin-2 receptor in 12 patients with adult-onset Still’s disease after effective therapy. Data are presented
as mean ± standard error of the mean. *P <0.005 versus before treatment, determined by the Wilcoxon signed rank test. AOSD: adult-onset Still’s
disease; GLK: germinal center kinase-like kinase; sIL-2R: soluble interleukin-2 receptor.
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support previous findings showing that MAPK pathway
plays an important role in the regulation of Th17 cell
function [33], and that IL-17 production is mediated by a
MAPK-dependent mechanism [34]. In addition, inhibi-
tion of MAPK could suppress IL-17 production in Vogt-
Koyanagi-Harada syndrome [35], and attenuate the
Th17-mediated autoimmune disease EAE [36]. These
observations suggest either GLK overexpression or
MAPK signaling can participate in the production of
Th17-related cytokines. However, there still exists the
possibility that GLK upregulation might represent an epi-
phenomenon of inflammation rather than a primary
event in the pathogenesis of AOSD.
Our longitudinal follow-up of patients with AOSD
showed a significant decrease in the levels of circulating
GLK-expressing T-cells as well as the expression levels of
GLK protein and transcript, paralleling the clinical remis-
sion and the decrease in inflammatory parameters after
effective therapy (Figure 4). Our results support the
hypothesis that inhibitors of more upstream MAPK sig-
naling pathways, such as MAP2K (MKK3 or MKK6) and
MAP3K (transforming growth factor activated kinase 1),
can be a promising therapeutic modality for rheumatic
diseases [37,38]. As an upstream MAPK, GLK could also
be targeted as a potential therapeutic strategy by broadly
inhibiting downstream MAPKs or several p38 isoforms
[39,40]. Furthermore, upstream signaling molecules
might be better targets than downstream molecules such
as p38MAPK, blockade of which could result in consider-
able toxic effects [37,41,42].
There were some limitations in this study. Because
biopsy tissue is difficult to obtain, we did not investigate
the GLK expression in lesion specimens from patients
with AOSD. Although some studies reported elevated
IL-1b levels in AOSD and a substantial benefit of IL-1b
receptor antagonist (anakinra) for treatment of inflam-
matory diseases [43,44], our results showed no signifi-
cant difference in IL-1b levels between patients with
AOSD and healthy volunteers. This discrepancy may
result from differences in the detection methods or
other unknown confounding factors undetected in this
study. The lack of any significant association of GLK
expression with clinical features may be owing to the
small sample size in this clinically heterogeneous and
uncommon disease.
Conclusions
Our results revealed that GLK overexpression with
increasing levels of Th17-related cytokines may be
involved in the pathogenic mechanisms of AOSD. Our
data add to the evidence supporting the association
between GLK overexpression and a list of inflammatory
diseases. We also showed that GLK expression levels
were positively correlated with disease activity of AOSD,
indicating that GLK might be a novel activity biomarker
and a potential therapeutic target. Further investigations
are required to confirm and extend this current finding.
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